Merck & Co. and Bayer’s Verquvo failed to deliver a composite cardiovascular benefit for certain patients with stable heart failure with reduced ejection fraction (HFrEF). The phase 3 Victor trial ...
Merck & Co. Inc. is buying Cidara Therapeutics Inc. for $9.2 billion to acquire a late-stage flu candidate and also to outrace blockbuster Keytruda’s looming patent expiration. CD-388, Cidara’s lead ...
Merck & Co. is stepping up to the plate to raise awareness of the dangers of high LDL cholesterol and how it can increase the risk of atherosclerotic cardiovascular disease (ASCVD). Joining the New ...
Merck is the latest pharmaceutical company to bring its educational disease state efforts to the baseball field. The company is rolling out its new cardiovascular health initiative, “Playing with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results